The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
NASH (Non-alcoholic Steatohepatitis) Biomarkers-Global Market Insights and Sales Trends 2025
Synopsis
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of NASH (Non-alcoholic Steatohepatitis) Biomarkers in various end use industries. The expanding demands from the Pharma & CRO Industry, Hospitals, Diagnostic Labs and Academic Research Institutes, are propelling NASH (Non-alcoholic Steatohepatitis) Biomarkers market. Serum Biomarkers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hepatic Fibrosis Biomarkers segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for NASH (Non-alcoholic Steatohepatitis) Biomarkers market, driven by demand from China, the second largest economy with some signs of stabilising, the NASH (Non-alcoholic Steatohepatitis) Biomarkers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for NASH (Non-alcoholic Steatohepatitis) Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, NASH (Non-alcoholic Steatohepatitis) Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of NASH (Non-alcoholic Steatohepatitis) Biomarkers covered in this report include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, Segment by Type:
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of NASH (Non-alcoholic Steatohepatitis) Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Non-alcoholic steatohepatitis is an advanced stage of non-alcoholic fatty liver disease (NAFLD), which arises when the excess fat accumulation causes inflammation and damage leading to liver scarring. A biomarker is the most effective diagnosis tool for measuring the biological state and is termed as an indicator for measuring normal biological processes and pathogenic process in the body.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market size is expected to reach US$ million by 2029, growing at a CAGR of % from 2023 to 2029. The market is mainly driven by the significant applications of NASH (Non-alcoholic Steatohepatitis) Biomarkers in various end use industries. The expanding demands from the Pharma & CRO Industry, Hospitals, Diagnostic Labs and Academic Research Institutes, are propelling NASH (Non-alcoholic Steatohepatitis) Biomarkers market. Serum Biomarkers, one of the segments analysed in this report, is projected to record % CAGR and reach US$ million by the end of the analysis period. Growth in the Hepatic Fibrosis Biomarkers segment is estimated at % CAGR for the next seven-year period.
Asia Pacific shows high growth potential for NASH (Non-alcoholic Steatohepatitis) Biomarkers market, driven by demand from China, the second largest economy with some signs of stabilising, the NASH (Non-alcoholic Steatohepatitis) Biomarkers market in China is forecast to reach US$ million by 2029, trailing a CAGR of % over the 2023-2029 period, while the U.S. market will reach US$ million by 2029, exhibiting a CAGR of % during the same period.
Report Objectives
This report provides market insight on the different segments, by manufacturers, by Type, by Application. Market size and forecast (2018-2029) has been provided in the report. The primary objectives of this report are to provide 1) global market size and forecasts, growth rates, market dynamics, industry structure and developments, market situation, trends; 2) global market share and ranking by company; 3) comprehensive presentation of the global market for NASH (Non-alcoholic Steatohepatitis) Biomarkers, with both quantitative and qualitative analysis through detailed segmentation; 4) detailed value chain analysis and review of growth factors essential for the existing market players and new entrants; 5) emerging opportunities in the market and the future impact of major drivers and restraints of the market.
Key Features of The Study:
This report provides in-depth analysis of the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, and provides market size (US$ million) and CAGR for the forecast period (2023-2029), considering 2022 as the base year.
This report profiles key players in the global NASH (Non-alcoholic Steatohepatitis) Biomarkers market based on the following parameters - company details (found date, headquarters, manufacturing bases), products portfolio, NASH (Non-alcoholic Steatohepatitis) Biomarkers sales data, market share and ranking.
This report elucidates potential market opportunities across different segments and explains attractive investment proposition matrices for this market.
This report illustrates key insights about market drivers, restraints, opportunities, market trends, regional outlook.
Key companies of NASH (Non-alcoholic Steatohepatitis) Biomarkers covered in this report include GENFIT SA, Gilead Sciences, Inc. (GILD), AstraZeneca, Novartis AG, Bristol-Myers Squibb Company, Allergan Plc, Novo Nordisk A/S, Boehringer Ingelheim and Pfizer Inc, etc.
The global NASH (Non-alcoholic Steatohepatitis) Biomarkers market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts.
Market Segmentation
Company Profiles:
GENFIT SA
Gilead Sciences, Inc. (GILD)
AstraZeneca
Novartis AG
Bristol-Myers Squibb Company
Allergan Plc
Novo Nordisk A/S
Boehringer Ingelheim
Pfizer Inc
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, by region:
North America (U.S., Canada, Mexico)
Europe (Germany, France, UK, Italy, etc.)
Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)
South America (Brazil, etc.)
Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, Segment by Type:
Serum Biomarkers
Hepatic Fibrosis Biomarkers
Apoptosis Biomarkers
Oxidative Stress Biomarkers
Others
Global NASH (Non-alcoholic Steatohepatitis) Biomarkers market, by Application
Pharma & CRO Industry
Hospitals
Diagnostic Labs
Academic Research Institutes
Core Chapters
Chapter One: Introduces the study scope of this report, executive summary of market segments by Type, market size segments for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Two: Detailed analysis of NASH (Non-alcoholic Steatohepatitis) Biomarkers manufacturers competitive landscape, price, sales, revenue, market share and ranking, latest development plan, merger, and acquisition information, etc.
Chapter Three: Sales, revenue of NASH (Non-alcoholic Steatohepatitis) Biomarkers in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the future development prospects, and market space in the world.
Chapter Four: Introduces market segments by Application, market size segment for North America, Europe, Asia Pacific, South America, Middle East & Africa.
Chapter Five, Six, Seven, Eight and Nine: North America, Europe, Asia Pacific, South America, Middle East & Africa, sales and revenue by country.
Chapter Ten: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter Eleven: Analysis of industrial chain, key raw materials, manufacturing cost, and market dynamics. Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter Twelve: Analysis of sales channel, distributors and customers.
Chapter Thirteen: Research Findings and Conclusion.
Index1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Overview
1.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Overview
1.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segment by Type
1.2.1 Serum Biomarkers
1.2.2 Hepatic Fibrosis Biomarkers
1.2.3 Apoptosis Biomarkers
1.2.4 Oxidative Stress Biomarkers
1.2.5 Others
1.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Type
1.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Overview by Type (2018-2029)
1.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size Review by Type (2018-2023)
1.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Type (2024-2029)
1.4 Key Regions Market Size Segment by Type
1.4.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Type (2018-2023)
1.4.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Type (2018-2023)
1.4.3 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Type (2018-2023)
1.4.4 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Type (2018-2023)
1.4.5 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Type (2018-2023)
2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competition by Company
2.1 Global Top Players by NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (2018-2023)
2.2 Global Top Players by NASH (Non-alcoholic Steatohepatitis) Biomarkers Revenue (2018-2023)
2.3 Global Top Players by NASH (Non-alcoholic Steatohepatitis) Biomarkers Price (2018-2023)
2.4 Global Top Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Manufacturing Base Distribution, Sales Area, Product Type
2.5 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Competitive Situation and Trends
2.5.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Concentration Rate (2018-2023)
2.5.2 Global 5 and 10 Largest Manufacturers by NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales and Revenue in 2022
2.6 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) & (based on the Revenue in NASH (Non-alcoholic Steatohepatitis) Biomarkers as of 2022)
2.7 Date of Key Manufacturers Enter into NASH (Non-alcoholic Steatohepatitis) Biomarkers Market
2.8 Key Manufacturers NASH (Non-alcoholic Steatohepatitis) Biomarkers Product Offered
2.9 Mergers & Acquisitions, Expansion
3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Status and Outlook by Region
3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size and CAGR by Region: 2018 VS 2022 VS 2029
3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Region
3.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2018-2023)
3.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Region (2018-2023)
3.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (Volume & Value) Price and Gross Margin (2018-2023)
3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Region
3.3.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2024-2029)
3.3.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Region (2024-2029)
3.3.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales (Volume & Value), Price and Gross Margin (2024-2029)
4 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers by Application
4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Segment by Application
4.1.1 Pharma & CRO Industry
4.1.2 Hospitals
4.1.3 Diagnostic Labs
4.1.4 Academic Research Institutes
4.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size by Application
4.2.1 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Overview by Application (2018-2029)
4.2.2 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size Review by Application (2018-2023)
4.2.3 Global NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Application (2024-2029)
4.3 Key Regions Market Size Segment by Application
4.3.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Application (2018-2023)
4.3.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Application (2018-2023)
4.3.3 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Application (2018-2023)
4.3.4 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Application (2018-2023)
4.3.5 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales Breakdown by Application (2018-2023)
5 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
5.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Country
5.1.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
5.1.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2018-2023)
5.1.3 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2018-2023)
5.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Country
5.2.1 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2024-2029)
5.2.2 North America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2024-2029)
6 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
6.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Country
6.1.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
6.1.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2018-2023)
6.1.3 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2018-2023)
6.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Country
6.2.1 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2024-2029)
6.2.2 Europe NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2024-2029)
7 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers by Region
7.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Region
7.1.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate (CAGR) by Region: 2018 VS 2022 VS 2029
7.1.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2018-2023)
7.1.3 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Region (2018-2023)
7.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Region
7.2.1 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Region (2024-2029)
7.2.2 Asia-Pacific NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Region (2024-2029)
8 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
8.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Country
8.1.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
8.1.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2018-2023)
8.1.3 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2018-2023)
8.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Country
8.2.1 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2024-2029)
8.2.2 Latin America NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2024-2029)
9 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers by Country
9.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Historic Market Size by Country
9.1.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Size Growth Rate (CAGR) by Country: 2018 VS 2022 VS 2029
9.1.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2018-2023)
9.1.3 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2018-2023)
9.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Forecasted Market Size by Country
9.2.1 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Volume by Country (2024-2029)
9.2.2 Middle East and Africa NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales in Value by Country (2024-2029)
10 Company Profiles
10.1 GENFIT SA
10.1.1 GENFIT SA Company Information
10.1.2 GENFIT SA Introduction and Business Overview
10.1.3 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.1.4 GENFIT SA NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.1.5 GENFIT SA Recent Development
10.2 Gilead Sciences, Inc. (GILD)
10.2.1 Gilead Sciences, Inc. (GILD) Company Information
10.2.2 Gilead Sciences, Inc. (GILD) Introduction and Business Overview
10.2.3 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.2.4 Gilead Sciences, Inc. (GILD) NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.2.5 Gilead Sciences, Inc. (GILD) Recent Development
10.3 AstraZeneca
10.3.1 AstraZeneca Company Information
10.3.2 AstraZeneca Introduction and Business Overview
10.3.3 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.3.4 AstraZeneca NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.3.5 AstraZeneca Recent Development
10.4 Novartis AG
10.4.1 Novartis AG Company Information
10.4.2 Novartis AG Introduction and Business Overview
10.4.3 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.4.4 Novartis AG NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.4.5 Novartis AG Recent Development
10.5 Bristol-Myers Squibb Company
10.5.1 Bristol-Myers Squibb Company Company Information
10.5.2 Bristol-Myers Squibb Company Introduction and Business Overview
10.5.3 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.5.4 Bristol-Myers Squibb Company NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.5.5 Bristol-Myers Squibb Company Recent Development
10.6 Allergan Plc
10.6.1 Allergan Plc Company Information
10.6.2 Allergan Plc Introduction and Business Overview
10.6.3 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.6.4 Allergan Plc NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.6.5 Allergan Plc Recent Development
10.7 Novo Nordisk A/S
10.7.1 Novo Nordisk A/S Company Information
10.7.2 Novo Nordisk A/S Introduction and Business Overview
10.7.3 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.7.4 Novo Nordisk A/S NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.7.5 Novo Nordisk A/S Recent Development
10.8 Boehringer Ingelheim
10.8.1 Boehringer Ingelheim Company Information
10.8.2 Boehringer Ingelheim Introduction and Business Overview
10.8.3 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.8.4 Boehringer Ingelheim NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.8.5 Boehringer Ingelheim Recent Development
10.9 Pfizer Inc
10.9.1 Pfizer Inc Company Information
10.9.2 Pfizer Inc Introduction and Business Overview
10.9.3 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Sales, Revenue and Gross Margin (2018-2023)
10.9.4 Pfizer Inc NASH (Non-alcoholic Steatohepatitis) Biomarkers Products Offered
10.9.5 Pfizer Inc Recent Development
11 Upstream, Opportunities, Challenges, Risks and Influences Factors Analysis
11.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Key Raw Materials
11.1.1 Key Raw Materials
11.1.2 Key Raw Materials Price
11.1.3 Raw Materials Key Suppliers
11.2 Manufacturing Cost Structure
11.2.1 Raw Materials
11.2.2 Labor Cost
11.2.3 Manufacturing Expenses
11.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industrial Chain Analysis
11.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Dynamics
11.4.1 NASH (Non-alcoholic Steatohepatitis) Biomarkers Industry Trends
11.4.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Drivers
11.4.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Challenges
11.4.4 NASH (Non-alcoholic Steatohepatitis) Biomarkers Market Restraints
12 Market Strategy Analysis, Distributors
12.1 Sales Channel
12.2 NASH (Non-alcoholic Steatohepatitis) Biomarkers Distributors
12.3 NASH (Non-alcoholic Steatohepatitis) Biomarkers Downstream Customers
13 Research Findings and Conclusion
14 Appendix
14.1 Research Methodology
14.1.1 Methodology/Research Approach
14.1.2 Data Source
14.2 Author Details
14.3 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
